Novo Nordisk (NVO) has resolved its shortage of weight-loss drugs Ozempic and Wegovy, according to a US Food and Drug Administration website update.
The resolved shortage issue means other companies will no longer be legally allowed to use copies of semaglutide, which is the generic name for the drugs.
Shares of Novo Nordisk were up 3.9% in recent trading following the FDA's announcement, while shares of Hims & Hers Health (HIMS) were down 24%.
Price: 86.79, Change: +3.05, Percent Change: +3.64
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。